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A new autosomal dominant eye and 
lung syndrome linked to mutations 
in TIMP3 gene
Isabelle Meunier1, Béatrice Bocquet1, Gilles Labesse2, Christina Zeitz3, Sabine Defoort-
Dhellemmes4, Annie Lacroux1, Martine Mauget-Faysse5, Isabelle Drumare4, Anne-
Sophie Gamez6, Cyril Mathieu7, Virginie Marquette1, Lola Sagot1, Claire-Marie Dhaenens8, 
Carl Arndt9, Patrick Carroll1, Martine Remy-Jardin10, Salomon Yves Cohen11, José-Alain Sahel3, 
Bernard Puech4, Isabelle Audo3, Sarah Mrejen5 & Christian P. Hamel1
To revisit the autosomal dominant Sorsby fundus dystrophy (SFD) as a syndromic condition including 
late-onset pulmonary disease. We report clinical and imaging data of ten affected individuals from 2 
unrelated families with SFD and carrying heterozygous TIMP3 mutations (c.572A > G, p.Y191C, exon 5, 
in family 1 and c.113C > G, p.S38C, exon 1, in family 2). In family 1, all SFD patients older than 50 (two 
generations) had also a severe emphysema, despite no history of smoking or asthma. In the preceding 
generation, the mother died of pulmonary emphysema and she was blind after the age of 50. Her two 
great-grandsons (<20 years), had abnormal Bruch Membrane thickness, a sign of eye disease. In family 
2, eye and lung diseases were also associated in two generations, both occurred later, and lung disease 
was moderate (bronchiectasis). This is the first report of a syndromic SFD in line with the mouse model 
uncovering the role of TIMP3 in human lung morphogenesis and functions. The TIMP3 gene should be 
screened in familial pulmonary diseases with bronchiectasis, associated with a medical history of visual 
loss. In addition, SFD patients should be advised to avoid tobacco consumption, to practice sports, and 
to undergo regular pulmonary examinations.
Sorsby fundus dystrophy (SFD, MIM 136900) is a rare autosomal dominant retinal dystrophy described by 
Sorsby, Mason and Gardener in 19491. SFD is characterized by bilateral deposition of yellow drusen-like material 
and extensive choroidal neovascularization (CNV) occurring between the third to fifth decades of life. Despite 
variable and confounding phenotypes, this dystrophy should be considered in patients with early neovasculariza-
tion in absence of predisposing factors such as high myopia, or with irregular thickening of the Bruch membrane 
as shown on SD-OCT.
Weber and al. published in 1994 the first causal heterozygous mutation in the tissue inhibitor of metallo-
proteinases -3 (TIMP3, 22q12.3, 5 exons) in a family with SFD2. The autosomal dominant inheritance was fur-
ther confirmed in all families, including those with a presumed recessive trait. TIMP3 as well as TIMP1 and 
TIMP2 regulate extracellular matrix renewal by the inhibition of matrix metalloproteinases (MMP). TIMPs form 
complexes with MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14 and MMP-15 and irreversibly 
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inactivate them by binding to their catalytic zinc cofactor. The NH2-terminal domain of TIMP1, TIMP2 and 
TIMP3 is responsible for MMP inhibition, whereas the COOH-terminal domain is involved in additional 
functions of the protein. In the retina, TIMP3 interacts with epithelial growth factor-containing fibulin-like 
extracellular matrix protein 1 (EFEMP1) and blocks the binding of VEGF to VEGFR2 resulting in inhibition 
of angiogenesis3–13. The majority of known mutations in TIMP3 underlying SFD are located in exon 5, with a 
substitution by a cysteine residue in most cases (for examples codons 174, 177 and 191). In the eye, Sorsby fundus 
retinal dystrophy is then characterized by a thickening of Bruch Membrane and subsequent risk of choroidal neo-
vascularization after the age of 40. The thickening of Bruch Membrane in SFD is located between the basement 
membrane of the RPE and the inner collagenous zone as previously reported in electron microscopic studies14,15. 
The current pathological hypothesis is that TIMP3 mutants with unpaired cysteine residue lead to the formation 
and accumulation of dimers in the extracellular matrix (ECM, Bruch Membrane). Bruch Membrane thickening 
contributes to a relative hypoxia and a dysfunction of the RPE with occurrence of choroidal neovascularization 
and progressive RPE loss.
Chronic Obstructive Pulmonary Disease (COPD) is characterized by an irreversible airflow limitation, caused 
by an increase in the resistance of the small conducting airways and in lung compliance due to emphysema16–20. 
The main causes are tobacco smoking together with atmospheric and domestic pollution. As only 15 to 20% 
smokers develop the disease, genetic factors could be involved in the pathogenesis. To date, polymorphisms in 
metalloproteinases (MMP3, MMP9) and their inhibitors (TIMP2, TIMP3) have been shown to be implicated21,22.
So far, SFD was strictly considered as an ocular disease. We report herein for the first time two unrelated fam-
ilies carrying heterozygous mutations in TIMP3 with an autosomal dominant syndromic form of SFD associated 
with pulmonary disease.
Results
Clinical findings. All SFD patients older than 55 years had pulmonary involvement either moderate (asymp-
tomatic air trapping) or severe (severe panlobular emphysema, very severe obstruction and chronic respiratory 
failure).
Family 1. Ocular involvement. In this family (Figs 1 and 2), the 5 patients older than 30 had extensive bilateral 
CNV with diffuse drusen-like changes (Table 1). CNV occurred at a young age (23 to 40 years). The oldest patient 
complained of moderate night-blindness. All were legally blind except patient IV:1, who received intravitreal 
injections of anti-vascular endothelial growth factor (bevacizumab) and retained 20/20 best-corrected visual acu-
ity in the right eye. The grand-mother (II:3) of patient IV:1 was legally blind after the age of 50. The two younger 
boys (V:1, V:2) were asymptomatic, but their Bruch Membrane was abnormally thickened on SD-OCT.
Figure 1. Family 1 with SFD and severe pulmonary disease linked to c.572A  > G TIMP3 mutation 
(squares = men and circles = women, black = SFD, blue = pulmonary disease, M/+: affected patients and 
+/+: wild type). 
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Pulmonary involvement. Without smoking exposure or any other pulmonary disease, generation III (70, 67, 59 
and 53 years) had airflow limitation with a reduction of (FEV1) between 28% and 73% (according to American 
Figure 2. Family 1. Color fundus photographs. (A,B) The youngest patient (V:2 ) had a normal fundus 
appearance. His father (C,D- IV:1) had a severe macular scarring in his left eye (D) and a preserved macula 
in his right eye by the use of anti-VEGF injections (C). Patients III:3 (E,F) and III:4 (G,H) had severe macular 
lesions.
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and European Thoracic Society criteria). On CT scans, these patients showed air trapping and abnormal bron-
chial wall thickening with mild basal bronchiectasis (Fig. 3). Two of them (III:1 and III:2)had chronic respiratory 
failure with oxygen supplementation. Their mother (II:3) died from severe emphysema. Patients IV:1 (44 years) 
had air trapping on chest tomography with normal pulmonary function tests. Patient V:1 (16 years) had air 
trapping and hypoxemia (79 mmHg) at rest. This patient had also complex cardiac congenital malformation with 
ventricular septal defect, obstruction of the right ventricular outflow tract, mitral valve dysplasia and hypoplasia 
of the left ventricle. An emergency surgical procedure was performed at 15 days of life for cyanosis. His brother 
V:2 (14 years) had a normal thoracic tomography and normal pulmonary function tests at rest.
Family 2. Ocular involvement. Night blindness, reported after the age of 45 was the first symptom in this 
family (Figs 4 and 5) (Table 1). At onset, multiple diffuse drusen-like accumulations or large yellow lesions were 
observed at the posterior pole and in the whole peripheral retina. In patients III:2- 3 and 6, after the age of 40 to 
50 years, best-corrected visual acuity decreased rapidly in both eyes in less than 10 years due to recurrent and 
extensive choroidal neovascularization. At the final stage, extensive subretinal fibrosis and macular atrophy with 
pigmentary changes were observed in both eyes (Fig. 5). The mother (patient II:2) carried the presumed diagnosis 
of macular degeneration and was blind before 60 years.
Pulmonary involvement. In this family, the two living patients of generation III underwent chest CT and had 
mild to marked bronchial wall thickening with mild cylindrical bronchiectasis in a single case (Fig. 6). None had 
CT features of emphysema. The mother II:2 developed after the age of 70 years atypical asthma with no history 
of smoking.
Genetic findings. Family 1. We found the TIMP3 variation c.572A > G (p.Y191C) in exon 5, previously 
described in a family with isolated SFD (initially p.Y168C)2. This variation is considered to be probably damag-
ing by PolyPhen 2 with a score = 1 (http://genetics.bwh.harvard.edu/pph2), damaging according to SIFT with a 
score = 0 (http://sift.jcvi.org), and to interfere most likely with the function of the protein by the align-GVDG 
program with a class C65 (http://agvgd.iarc.fr/agvgd_input.php), disease causing for mutation taster with a prob-
ability of 0.99 (www.mutationtaster.org), and neutral for Provean (provean.jcvi.org). The mutation co-segregated 
with the disease in the family and is not reported in the ExAc database (http://exac.broadinstitute.org).
Multiple amino-acid sequence alignment of TIMP3 orthologs showed the conservation of the leucine at posi-
tion 191 in all eukaryotic sequences available. According to Nextprot database (www.nextprot.org), this mutation 
has been noted in several families since the initial identification of TIMP32,23.
Patient Gender Onset
Age at 
examination
Visual acuity at 
Examination
Age at CNV 
occurrence
Chest computed 
tomography
Family 1: Mutation in TIMP3, exon 5, c.Y191C
 III:1 M 40 65
RE: CF RE: 40
Severe emphysema
LE: CF LE: 42
 III:2 F 39 68
RE: CF RE: 39
Severe emphysema
LE: CF LE: 43
 III:3 M 34 60
RE: CF RE: 34
Mild emphysema
LE: 20/400 LE: 40
 III:4 F 29 54
RE:20/200 RE: 29 Mild emphysema
LE:20/200 LE: 33
 IV:1 M 23 45
RE:20/20 RE: 35
Air trapping
LE:20/200 LE: 23
 V:1 M asymptomatic 16
RE:20/20 No CNV Air trapping 
(cardiac 
malformation)LE:20/20 RE-LE
 V:2 M asymptomatic 14
RE:20/20 No CNV
Normal imaging
LE:20/200 RE-LE
Family 2 Mutation in TIMP3, exon 1, c.S38C
 III:2 M 50 72
RE: CF No CNV Air trapping 
BronchiectasisLE: CF RE-LE
 III:3 M 40 deceased
RE: CF RE: 40
Not practiced 
DeceasedLE: CF LE: No CNV
 III:6 F 49 73
RE: CF No CNV Air trapping 
BronchiectasisLE: CF RE-LE
Table 1.  Clinical data of patients with Sorsby fundus dystrophy. M: male. F: female. Onset: age of onset i.e., 
symptomatic stage. Age: age at examination. RE: right eye. LE: left eye. CNV: choroidal neovascularization.  
CF: counting fingers.
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Family 2. We found the TIMP3 variation c.113C > G (p.S38C) in exon 1 which has been previously described in 
SFD24. This variation is considered to be probably damaging by PolyPhen 2 with a score = 1 (http://genetics.bwh.
harvard.edu/pph2), damaging according to SIFT with a score = 0 (http://sift.jcvi.org), and to interfere most likely 
with the function of the protein by the align-GVDG program with a class C65 (http://agvgd.iarc.fr/agvgd_input.
php), disease causing for mutation taster with a probability of 0.99 (www.mutationtaster.org), and deleterious for 
Provean (provean.jcvi.org). This variation is not present in ExAC. In addition, the mutation co-segregated with 
the disease in the family. This mutation has been reported previously in 5 SFD unrelated patients24,25.
Discussion
This is the first report of a syndromic association of autosomal dominant SFD with an autosomal dominant 
pulmonary disease. This latter aspect is characterized by distal bronchiolar and alveolar dysfunctions leading to 
a chronic obstructive pulmonary disease in absence of asthma and tobacco consumption. In addition, the basal 
Figure 3. High resolution computed tomographic scans of patients III:3 (A) and III:2 (B). On CT scans, note 
bronchiectasis, diffuse bronchial wall thickening (large arrows), air trapping and emphysema bullae (thin 
arrows). These lesions are localized at the basal part of the lung, and not at the apex as noted in smokers. Patient 
III:2 uses domiciliary oxygen.
Figure 4. Pedigree of family 2 with SFD and late moderate pulmonary disease linked to c.113C > G TIMP3 
mutation. (squares = men, circles women, black = SFD and blue = pulmonary disease, M/+ : affected patients 
and + /+ : wild type).
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location of pulmonary lesions is not in keeping with COPD secondary to smoking. In these families, the two 
oldest generations developed pulmonary lesions in line with an autosomal dominant transmission and with an 
extracellular matrix remodeling disease (Bruch Membrane in the eye). Indeed, there are several experimental 
data that plead for the pathological role of TIMP3 mutations in the pulmonary disease.
First, TIMP3 is highly expressed in the lung. Its role in this organ was well established in developmental 
phases, in resolution of inflammation following lung injury and in idiopathic pulmonary fibrosis26–28. At the 
developmental stage, bronchiole branching morphogenesis depends on interactions between the bronchiole 
epithelium, the mesenchyme and the extracellular matrix or basement membrane which serves as an inter-
face between the two compartments. Remarkably, it was shown that in Timp3-/- null mice, enhanced MMP 
activity interferes with extra cellular matrix proteolysis, perturbing the formation of the bronchiole tree dur-
ing morphogenesis. These homozygous mice have abnormal bronchiolar morphology and respiratory dysfunc-
tion with reduction in carbon monoxide uptake and a progressive increased alveolar size proved by a decline in 
hydroxy-proline content (http://www.informatics.jax.org/allele/genoview/MGI:3056101).
Another aspect of the role of TIMP3 in the pulmonary disease is its involvement in the resolution of inflam-
mation following lung injury, by regulating the neutrophil influx in the injury site. In Timp3-/- mice, the 
Figure 5. Color fundus photographs. (A) Patient III:2 at the age of 55, note the numerous drusen-like lesions 
and yellow large material all over the retina. (B) Same patient at the age of 81, macular atrophy occurred with 
subsequent ambulatory vision loss. (C) Patient III:6 at the age of 57, note the atrophic lesions at the posterior 
pole in the right eye. (D) Same patient at the age of 65.
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inflammation persisted up to 28 days with increased neutrophil chemotactic activity28. This prolonged abnormal 
response was reversed under synthetic inhibitor of MMP. In addition, in idiopathic pulmonary fibrosis charac-
terized by fibroblast expansion and extracellular matrix accumulation, TIMP3 gene expression is increased and 
the protein is localized to fibroblastic foci and extracellular matrix. This dysregulation of ECM remodeling could 
involve in the lung the p38 kinase pathway and the TGF-beta1 which are important mediators in lung fibrosis.
The role of polymorphisms in metalloproteinases (MMP3-MMP9, ADAM33) and their inhibitors (TIMP2 
and TIMP3) in the onset and severity of COPD in smokers has been reported21,22. In our families, a mutation 
in TIMP3 is also probably the cause of the autosomal dominant lung disease with lung extracellular matrix 
damaging.
This syndromic disease could be unsuspected because the pulmonary disease starts one to three decades after 
visual loss. For example, in our family 2, pulmonary involvement was only confirmed by CT imaging. This new 
syndrome has an autosomal dominant inheritance as it concerns three generations (6 patients) in family one and 
two generations (three patients) in family two.
To shed light on the potential impact of the two mutations and differences of disease onset or severity, a the-
oretical model of the full-length TIMP3 was based on the crystal structure of TIMP2 and TIMP3 as a combined 
template using the server @TOME-2 (Pons et Labesse 2009)29,30. The differences in lung severity involvement 
between families 1 and 2 could be linked with both the type of substitutions/mutations (non-conservative/con-
servative, respectively) and their locations in distinct domains (C-terminal and N-terminal respectively, Fig. 7). 
Indeed, in family 1, a large and hydrophobic residue is substituted by a small cysteine while in the family 2, a ser-
ine is substituted by an isosteric cysteine. Furthermore, in the first case, the additional cysteine lies spatially close 
to two disulphide bridges (C145–C192; C163, C184) and it may interfere with them especially during TIMP3 
folding and maturation. In the second case, the substitution occurs further from any other cysteines (C36–C143). 
Finally, the two mutated sites correspond to two distinct protein-protein interaction sites. The mutation p.S38C is 
located at the interface with the MMPs and is not predicted to affect significantly the binding affinity. On the con-
trary, due to a more pronounced change in amino-acid size, the mutation p.Y191C could impact more dramati-
cally on the interaction with EFEMP1 which has been mapped to the C-terminal part of TIMP313. Accordingly, 
the mutation in family 1 is predicted to be more detrimental to the protein function and/or stability than the sec-
ond mutation. It should be noted that EFEMP1 is also expressed in the lung, but we cannot exclude that TIMP3 
interacts with a distinct lung specific molecule. Regarding SFD, CNV occurred during the third and fourth dec-
ades in family 1 versus the fifth decade for family 2. The other reported cases with p.S38C and p.Y191C displayed 
similar differences in age of onset2,23–25.
In conclusion, Sorsby fundus dystrophy should be reappraised as a syndromic condition with a risk of late 
onset bronchiolar and pulmonary disease. SFD patients should avoid tobacco smoking and practice sports. 
Furthermore, a pulmonary disease should be investigated after the age of 55. In this line, TIMP3 should be 
screened in patients with familial bronchiectasis or emphysema, particularly if a medical history of visual loss or 
choroidal neovascularization is reported.
Patients and Methods
Informed consent was obtained for clinical examination and genetic analysis from all patients. All methods were 
carried out in accordance with approved protocols of Montpellier and Lille University Hospitals, and in agree-
ment with the Declaration of Helsinki. The Ministry of Public Health accorded approval for biomedical research 
under the authorization number 11018S.
Clinical and functional retinal evaluation. For each patient, age at examination, refraction, initial and 
final best-corrected visual acuity were noted. The best-corrected visual acuity was obtained with Snellen charts. 
Near visual acuity was assessed with the current French near vision chart (Parinaud). Color fundus photo-
graphs were performed with Topcon Imagenet (Ophthalmic Imaging Systems, Japan) or Nidek non-mydriatic 
automated fundus camera AFC 330 (Nidek Inc, Japan). Autofluorescence imaging and spectral domain optical 
Figure 6. High resolution CT scan. (A) Patient III:6, note mild cylindered bronchiectasis in both lower lobes 
(white arrows). (B) Patient III:2, there is marked bronchial wall thickening on both sides (whites arrows).
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coherent tomography were performed with Combined Heidelberg Retina Angiograph + OCT Spectralis device 
(Heidelberg Engineering, Dossenheim, Germany).
Pulmonary evaluation. Chest computed tomography (CT). We performed high-resolution chest CT scans 
in 8 patients (6 in family 1 and 2 in family 2). Chest CT was obtained on different multi-detector (MDCT) scan-
ners, including a 64-slice MDCT equipment (SOMATON Definition AS+ , SIEMENS, Healthcare, Forchheim, 
Germany) and a third-generation, dual source CT scanner (SOMATOM Force, SIEMENS Healthcare, Forchheim, 
Germany) detectors. The scanning protocol included end-inspiratory and -expiratory acquisitions over the entire 
thorax. The CT parameters analyzed on lung images included emphysema (i.e., centrilobular, panlobular, bul-
lous), bronchial wall thickening, bronchiectasis and CT features of small airways disease (i.e., bronchiolectases, 
ill-defined micronodules, mosaic attenuation and air trapping) on lung images.
Pulmonary function test. Spirometry was performed in all affected patients of family 1, in accordance with 
American Thoracic Society standards19,31. Values of percent-predicted for spirometry were calculated using refer-
ence values based on age, height, sex and race19,31. The basic parameters used to properly interpret lung function 
were forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and FEV1/FVC ratio. Airway obstruc-
tion was defined by reduction of the FEV1/FVC ratio (also known as Tiffeneau-index) below 70%.
Genetic analysis. Genomic DNA was extracted using a standard salting-out procedure. All exons of TIMP3 
(refseq NG_009117.1) were screened in all patients. The screening was performed on genomic DNA using primers 
designed to flank the splice junctions of each exon (sequences available upon request). After standard polymerase 
chain reaction (PCR) amplification, products were purified with ExoSAP-IT (GE Healthcare Life Sciences, USB 
Corporation) and direct sequencing was performed on an Applied Biosystems (ABI) 3130 xL genetic analyzer 
(Applied BioSystems, Foster City, CA, USA) using the BigDye Terminator Cycle Sequencing Ready Reaction kit 
V3.1. Sample sequences were aligned to the wild-type sequence and analyzed with the Collection and Sequence 
Analysis software package (Applied Biosystems).
The pathogenicity of nucleotide changes was estimated by different predictive software including, Polyphen 
program - Harvard University, Boston, MA. http://genetics.bwh.harvard.edu/pph, SIFT (http://sift.jcvi.org), 
Align-GVDG program (http://agvgd.iarc.fr/agvgd_input.php), Mutation taster (www.mutationtaster.org), and 
Provean (provean.jcvi.org). The pathogenicity was also assessed considering multiple-amino-acid sequence align-
ment of TIMP3 orthologs and the protein structure identity according to Nextprot database (www.nextprot.org). 
Indeed, the variation had to segregate with the disease in the family. The identified variations were tracked in all 
genetic databases and in previous articles about Sorsby fundus dystophy.
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